Krystal Biotech: Toward the Future of Gene Therapy with a gel

Redosable gene therapy for a rare skin disease as a high-margin core product Platform story from skin to lung and eye for ambitious growth investors At first glance, Krystal Biotech appears to be a typical specialty biotech: small to mid-sized market capitalization, one approved drug for a rare disease, and a handful of projects in clinical development. There are no major marketing campaigns, no broad media presence – rather a stock that is primarily on the radar of specialists and niche healthcare investors. However, behind this...